MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,666.45
+0.19%
NASDAQ 100
$30,501.56
+0.31%
DOW JONES
$50,927.00
+0.04%
NASDAQ Composite
$26,871.60
+0.04%
RUSSELL 2000
$2,790.20
+0.41%
CBOE VIX
$16.39
+0.31%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
ANRO — Alto Neuroscience Inc.
NYSEAlto Neuroscience Inc.
$24.80
-0.51(-2.02%)
- O
- 25.64
- H
- 26.10
- L
- 23.87
- V
- 660.68K
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About ANRO
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateFeb 2, 2024
Employees68
Stock ExchangeNYSE
Ticker SymbolANRO
Key Financial Statistics
| Market Cap | $1.04B |
| P/E Ratio | N/A |
| Dividend Yield | N/A |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $1.60 - $37.48 |
| 52-Week Avg Volume | 472.3K |
| VWAP | $24.54 |
| Transactions | 10,931 |
| Total Recorded Bars | 669 days |